Lymphoma (follicular non-Hodgkin's) - rituximab
Rituximab for the treatment of relapsed or refractory stage III or IV follicular non-Hodgkin's lymphoma (review of technology appraisal guidance 37)
Summary
This guidance replaces NICE technology appraisal guidance 37 issued in March 2002. The Institute reviews each piece of guidance it issues. The review and re-appraisal of the use of rituximab for the treatment of relapsed or refractory stage III or IV follicular non-Hodgkin's lymphoma has resulted i ...
Guidance documents
Implementing this guidance
Other information
We will consult on our review plans for this guidance in December 2010
About this guidance
Technology appraisals TA137
Issued: February 2008
How this guidance was produced
